Interv Akut Kardiol. 2018;17(2):108-112 | DOI: 10.36290/kar.2018.046
Recent advances in the pharmacotherapy of cardiovascular diseases
- Ústav farmakologie 3. LF UK Praha
The present review of advances in the treatment of cardiovascular diseases deals with three areas: anti-inflammatory treatment of atherosclerosis,current effect of acetylsalicylic acid, and comparison of strategies for LDL-cholesterol reduction. The first part demonstratesthe possibility of anti-inflammatory treatment of atherogenesis with a monoclonal antibody (canakinumab) inactivating interleukin1β. The effect of inflammation in atherogenesis and thrombogenesis is demonstrated using additional examples – periodontitis oracute viral infection. The current effect of acetylsalicylic acid in women, the elderly, or diabetics has been confirmed based on thedata from a Swedish national registry. Termination of treatment resulted in a significant increase in atherothrombotic events, withthe increase being more significant when acetylsalicylic acid was indicated as part of secondary prevention. The use of acetylsalicylicacid is supported by an additional antitumour effect (particularly in the prophylaxis of colorectal cancer); this chemoprophylaxishas already been incorporated in the guidelines. The third part involves comparison of the importance of various hypolipidaemicstrategies aimed at LDL-cholesterol concentration. Based on a comparison of pharmacotherapy and genetic polymorphisms, it hasbeen shown that of crucial importance is the resulting decline in LDL-cholesterol, not the way it was achieved.
Keywords: atherogenesis, thrombogenesis, canakinumab, acetylsalicylic acid, hypolipidaemic drugs
Published: May 1, 2018 Show citation
References
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease, N Engl J Med 2017; 377: 1119-1131.
Go to original source... 
Go to PubMed... - Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013; 166(2): 199-207. Go to original source... Go to PubMed...
- Deanfield JE, Sellier P, Thaulow E, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? European Heart Journal. 2010; 31(21): 2650-2659. Go to original source... Go to PubMed...
- Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965. Go to original source... Go to PubMed...
- Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial, Circulation 2018, https://doi.org/10.1161/CIRCULATIONAHA.118.034032 Go to original source... Go to PubMed...
- Sen S, Giamberardino LD, Moss K, et al. Periodontal Disease, Regular Dental Care Use, and Incident Ischemic Stroke, Stroke. 2018;STROKEAHA.117.018990, https://doi.org/10.1161/STROKEAHA.117.018990 Go to original source... Go to PubMed...
- Kwong JC, Schwartz, KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018; 378: 345-353. Go to original source... Go to PubMed...
- Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86. https://pace-cme.org/2017/09/14/esc-grand-debate-aspirin-for-life/. Go to original source... Go to PubMed...
- Sundström J, et al. Low-dose aspirin discontinuation and risk of cardiovascular events a swedish nationwide, population-based cohort study, circulation. 2017; 136: 1183-1192. Go to original source... Go to PubMed...
- Chan AT, Ladabaum U. Where do we stand with aspirin for the prevention of colorectal cancer? The USPSTF Recommendations. Gastroenterology, 2016; 150: 14-18. Go to original source... Go to PubMed...
- Bibbins-Domingo K. On behalf of the U.S. Preventive services task force aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2016; 164: 836-845. Go to original source... Go to PubMed...
- Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527. Go to original source... Go to PubMed...
- Ornelas A, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention Cancer Metastasis Rev 2017; 36: 289-303. Go to original source... Go to PubMed...
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-2472. Go to original source... Go to PubMed...